Enrolled participants in ARAD will complete self administered surveys at 6-12 monthly intervals. Participants are asked to describe their health status, arthritis treatments and quality of life. ARAD is joining forces with the Australian Arthritis & Autoimmune Biobank Collaborative (A3BC). Visit their website for further information: https://a3bc.org.au/
Information collected from surveys in addition to linkages with other health organisations including the National Death Index, cancer registries, Medicare, and the Pharmaceutical Benefits Scheme is analysed regularly.
By collecting long-term information about people’s arthritis management, and their health and quality of life, ARAD aims to provide reliable and valid outcome data to Australian clinicians, consumers, policy makers, drug development companies and approval agencies. The project focuses on the impact of living with arthritis, and on the long term safety and efficacy of established and new generation ‘biological’ drugs.
ARAD is endorsed by the Australian Rheumatology Association and is being conducted on behalf of its members.
To review recent developments in ARAD, click here to download the latest participant newsletter.